- Home
- BCV vs SGMO Comparison
BCV vs SGMO Comparison
Compare BCV & SGMO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BCV | SGMO |
|---|---|---|
| Founded | 1971 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 128.4M | 141.2M |
| IPO Year | N/A | 2000 |
Fundamental Metrics
Financial Performance| Metric | BCV | SGMO |
|---|---|---|
| Price | $25.59 | $0.18 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $7.00 |
| AVG Volume (30 Days) | 13.9K | ★ 17.3M |
| Earning Date | 01-01-0001 | 05-07-2026 |
| Dividend Yield | ★ 8.13% | N/A |
| EPS Growth | N/A | ★ 10.20 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $36,567,000.00 |
| Revenue This Year | N/A | $107.15 |
| Revenue Next Year | N/A | $76.44 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 88.60 |
| 52 Week Low | $17.67 | $0.12 |
| 52 Week High | $25.44 | $0.77 |
Technical Indicators
Market Signals| Indicator | BCV | SGMO |
|---|---|---|
| Relative Strength Index (RSI) | 71.52 | 37.98 |
| Support Level | $21.22 | N/A |
| Resistance Level | N/A | $0.55 |
| Average True Range (ATR) | 0.42 | 0.03 |
| MACD | 0.06 | -0.01 |
| Stochastic Oscillator | 98.92 | 34.48 |
Price Performance
Historical ComparisonAbout BCV Bancroft Fund Ltd.
Bancroft Fund Ltd is a diversified closed-end management company. It operates as a closed-ended equity mutual fund. The funds' main objective is to provide income and potential for capital appreciation. With the intent to achieve its objective, the company invests in convertible and equity securities. It invests across different industries such as Computer Software and Services, Energy and Utilities, Health Care among others.
About SGMO Sangamo Therapeutics Inc.
Sangamo Therapeutics Inc is a genomic medicine company committed to translating ground-breaking science into medicines that transform the lives of patients and families afflicted with serious neurological diseases. Its pipeline products include the Priority Neurology Pipeline offers Chronic Neuropathic Pain, Prion Disease, and Neurology; Partnered Programs offer Hemophilia A, Oncology, ALS/FTD, and Huntington's Disease; and Other Pipelines include Fabry Disease, Renal Transplant, Inflammatory Bowel Disease, and Multiple Sclerosis.